Machine Learning Enabled Smartphone CRISPR-Cas12a Lateral Flow Platform for Sensitive Detection of Circulating HPV DNA
jiang, F.; Liao, J.; Rima, J.; Sharma, A.; Tsou, J.-H.
Show abstract
Persistent infection with high-risk human papillomavirus (HPV) is the primary cause of cervical cancer and other HPV-related malignancies. Effective screening and early detection of HPV, particularly in point-of-care (POC) settings, can reduce disease progression and associated mortality. Although PCR-based assays provide high sensitivity, their dependence on centralized laboratory infrastructure limits accessibility in POC settings. CRISPR-Cas diagnostics enable programmable, isothermal detection of HPV with lateral flow assay (LFA) readouts; however, visual interpretation of faint bands can be subjective and inconsistent. Our objective was to develop a machine learning (ML)-enhanced, smartphone-native CRISPR-LFA platform for highly sensitive and reliable detection of HPV DNA in plasma. A smartphone-based diagnostic system integrating CRISPR-LFA with a ML framework was developed using standardized image acquisition within a light-controlled enclosure. Radiomics-inspired strip features were extracted and analyzed using a multivariable logistic regression model. A total of 150 plasma samples were used for model development and 60 independent samples for validation. An optimized model was developed that had 96.7% sensitivity and 100% specificity for detection of HPV DNA. The smartphone-enabled CRISPR platform demonstrated higher sensitivity than visual interpretation, particularly for faint-band results, and reduced false positives. Validation in the independent cohort confirmed the robustness of the assay. Performance remained stable across smartphone models, lighting conditions, and operators, and on-device inference enabled reliable operation. In sum, the smartphone-integrated CRISPR-LFA platform can facilitate accurate and reliable detection of plasma HPV DNA in POC settings and has the potential to enhance early detection, prevention, and treatment of cervical cancer.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.